Relevant bibliographies by topics / Tasimelteon

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Tasimelteon'

Author: Grafiati
Published: 14 March 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Tasimelteon.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Tasimelteon"

1

Johnsa, Jessica D., and Michael W. Neville. "Tasimelteon." Annals of Pharmacotherapy 48, no. 12 (2014): 1636–41. http://dx.doi.org/10.1177/1060028014550476.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bonacci, Janene M., Jineane V. Venci, and Mona A. Gandhi. "Tasimelteon (Hetlioz™)." Journal of Pharmacy Practice 28, no. 5 (2014): 473–78. http://dx.doi.org/10.1177/0897190014544792.

Full text
Abstract:
In January 2014, the US Food and Drug Administration approved tasimelteon (Hetlioz™), a melatonin-receptor agonist for the treatment of non-24-hour sleep–wake disorder. This article provides an overview of the mechanism of action, pharmacokinetic properties, as well as the clinical efficacy, safety, and tolerability of tasimelteon. Relevant information was identified through a comprehensive literature search of several databases using the key words tasimelteon, Non-24-hour Sleep–Wake disorder, Non-24, and melatonin. Further information was obtained from the tasimelteon package insert, fda.gov
APA, Harvard, Vancouver, ISO, and other styles
3

Brooks, J., M. Gibson, K. Kite, et al. "1161 Tasimelteon Shows Persistence Of Efficacy In Improving Sleep Disturbances In Patients With Smith-Magenis Syndrome (SMS) In Open-Label Extension Study." Sleep 43, Supplement_1 (2020): A442—A444. http://dx.doi.org/10.1093/sleep/zsaa056.1155.

Full text
Abstract:
Abstract Introduction Smith-Magenis Syndrome (SMS) is a rare (1/15,000 - 25,000 births) neurodevelopmental disorder resulting from an interstitial deletion of chromosome 17p11.2, or from a point mutation in the RAI1 gene. Severe sleep disorder is almost universal in patients with SMS and poses a significant challenge to patients and their families. Tasimelteon improved sleep symptoms in a randomized, double-blind, two-period, crossover study; and here we show that this effect persists for up to four years in an open-label extension. To our knowledge, this is the largest interventional study of
APA, Harvard, Vancouver, ISO, and other styles
4

Lankford, D. Alan. "Tasimelteon for insomnia." Expert Opinion on Investigational Drugs 20, no. 7 (2011): 987–93. http://dx.doi.org/10.1517/13543784.2011.583235.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

&NA;. "Tasimelteon tackles chronic insomnia." Inpharma Weekly &NA;, no. 1645 (2008): 5. http://dx.doi.org/10.2165/00128413-200816450-00013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Torres, Rosarelis, Marlene A. Dressman, William G. Kramer, and Paolo Baroldi. "Absolute Bioavailability of Tasimelteon." American Journal of Therapeutics 22, no. 5 (2015): 355–60. http://dx.doi.org/10.1097/mjt.0000000000000195.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Li, Xi-An, Lirong Yue, Jianrong Zhu, et al. "Total synthesis of Tasimelteon." Tetrahedron Letters 60, no. 30 (2019): 1986–88. http://dx.doi.org/10.1016/j.tetlet.2019.06.048.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dhillon, Sohita, and Madeleine Clarke. "Tasimelteon: First Global Approval." Drugs 74, no. 4 (2014): 505–11. http://dx.doi.org/10.1007/s40265-014-0200-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

&NA;. "Tasimelteon helps transient insomniacs nod off." Inpharma Weekly &NA;, no. 1667 (2008): 11. http://dx.doi.org/10.2165/00128413-200816670-00033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Adams, Katie S., and Ericka L. Breden Crouse. "Melatonin agonists in the management of sleep disorders: A focus on ramelteon and tasimelteon." Mental Health Clinician 4, no. 2 (2014): 59–64. http://dx.doi.org/10.9740/mhc.n190087.

Full text
Abstract:
Melatonin agonists have become an area of interest in the treatment of sleep disorders. This article reviews the available data on this class of medications, with a focus on ramelteon and tasimelteon.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Tasimelteon"

1

CIANFEROTTI, CLAUDIO. "Synthetic approaches to novel linkers for the bioconjugation of pharmaceutical active compounds." Doctoral thesis, Università di Siena, 2019. http://hdl.handle.net/11365/1071010.

Full text
Abstract:
Gli Antibody-Drug Conjugates (ADC) sono tra i farmaci più promettenti per la terapia mirata antitumorale. Gli ADC sfruttano infatti la capacità degli anticorpi monoclonali di indirizzare il trasporto di molecole citotossiche in modo selettivo al sito del tumore, con un miglioramento dell’efficacia della sicurezza del farmaco citotossico. La porzione linker di collegamento tra l’anticorpo e il farmaco è una componente cruciale di ogni ADC: deve essere stabile in plasma ma instabile all’interno della cellula, permettendo il rilascio del farmaco citotossico solo nell’ambiente citoplasmatico ed ev
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Tasimelteon"

1

Blokdijk, G. J. Tasimelteon; Complete Self-Assessment Guide. CreateSpace Independent Publishing Platform, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Tasimelteon"

1

Neubauer, David N., Ahmed S. BaHammam, and Seithikurppu R. Pandi-Perumal. "Tasimelteon." In Drug Treatment of Sleep Disorders. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-11514-6_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"Tasimelteon." In What Your Patients Need to Know About Psychiatric Medications. American Psychiatric Association Publishing, 2016. http://dx.doi.org/10.1176/appi.books.9781615371280.rc14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"TAPENTADOL TASIMELTEON *." In Litt's Drug Eruption and Reaction Manual. CRC Press, 2015. http://dx.doi.org/10.1201/b17996-125.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Tasimelteon"

1

Steiger, A. "Tasimelteon reentrains sleep in a patient with phase delay syndrome." In Abstracts of the 30th Symposium of the AGNP. Georg Thieme Verlag KG, 2017. http://dx.doi.org/10.1055/s-0037-1606429.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Connolly, P. J., M. Quigg, and E. M. Davis. "Non-24-hour Sleep-wake Rhythm Disorder in Sighted Individual Treated With Tasimelteon." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5858.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Tasimelteon' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography